Radnostix, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Shahe Bagerdjian
- Full Time Employees
- 45
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4137 Commerce Circle Idaho Falls ID United States of America 83401
- IPO Date
- Aug 14, 1997
- CIK
- 0001038277
- Website
- radnostix.com
- Similar Companies
- Business
- International Isotopes Inc. specializes in the production and global distribution of specialized nuclear materials, including medical calibration standards, cobalt-60 offerings, and contract manufacturing for radiopharmaceutical and radiochemical applications. The company’s operations are organized across several distinct divisions: Calibration and Reference Products, Cobalt Products, Theranostics Products, Medical Devices, Radiological Services, and Fluorine Products. The Calibration and Reference Products segment crafts a comprehensive line of sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, patient positioning, and the precise calibration and functional assessment of dose measuring equipment within the nuclear pharmacy sector. This includes items such as flood sources, dose calibrators, various rod sources, flexible and rigid rulers, along with specific spot and pen point markers. Within the Cobalt Products division, the company manufactures bulk cobalt and fabricates cobalt capsules vital for radiation therapy, diverse industrial applications, including container security examinations, and also manages the recycling of depleted cobalt sources. Notably, International Isotopes Inc. stands as the sole domestic U.S. manufacturer of high-activity Cobalt-60 sealed-source products. The Theranostics Products segment is responsible for producing and supplying a range of isotopically pure radiochemicals, including the only FDA-approved generic sodium iodide I-131 drug product made in the United States, used for treating hyperthyroidism and thyroid cancer. This segment also offers active pharmaceutical ingredient (API) supply and contract manufacturing services for external theranostics clients. A recently established Medical Devices segment, which began reporting in fiscal year 2024, is actively developing and launching new products under its RadVent brand, such as the Swirler® and Tru-Fit™ product lines, aiming to enhance safety, efficiency, and patient access in radiopharmaceutical diagnostics and therapeutics. Additionally, the Radiological Services segment provides flood source disposal and gemstone processing, alongside custom shielding and encapsulation services. The Fluorine Products division focuses on developing and producing high-purity fluoride gas samples for industrial uses, while also advancing laboratory and analytical methods to support a planned uranium de-conversion and fluorine extraction facility. The company distributes its products directly to end-users and through various distributors. Established in 1995, International Isotopes Inc. maintains its corporate headquarters in Idaho Falls, Idaho.
Company News
Radnostix and NANO Nuclear Energy Announce Joint Submission of Letter of Intent to NRC Seeking Consent for Transfer of License SUB-1011, Following Lea County Approval of Property LOI
International Isotopes (OTCMKTS:INIS) Share Price Crosses Below 200-Day Moving Average – Should You Sell?
Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear
Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition
Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio
Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown
Radnostix, Inc. Reports FY2025 Results - Second-Highest Annual Revenue in Company History; Delivers Strong Growth in Calibration & Reference Products and Advances Key Product Launches in 2025
International Isotopes (OTCMKTS:INIS) Share Price Passes Below 200-Day Moving Average – Here’s What Happened
International Isotopes (OTCMKTS:INIS) Stock Price Passes Above Fifty Day Moving Average – Here’s Why
International Isotopes (OTCMKTS:INIS) Shares Cross Below 200 Day Moving Average – Time to Sell?
International Isotopes (OTCMKTS:INIS) Share Price Passes Above 50 Day Moving Average – Here’s Why
International Isotopes Inc. Announces Company Name Change to Radnostix, Inc.
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025
International Assets Investment Management LLC Has $11.20 Million Position in Alphabet Inc. $GOOGL
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FIRST QUARTER 2025
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2024
International Isotopes, Inc. Expands Operational Footprint with Strategic Land Acquisition and Additional New Facility Lease Agreement
International Isotopes, Inc. Announces the Amendment of the Acquisition of the AMICI, Inc. Product Line
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2024